Safety and Tolerability of Human Placenta-Derived Cells (PDA001) in Treatment-Resistant Crohn’s Disease A Phase 1 Study

The clinical utility of cellular therapies is being investigated in a broad range of therapeutic areas. This phase 1 study represents the first exploration of PDA001, a preparation of cells cultured from human placental tissue, in subjects with Crohn's disease. Twelve subjects with active, mode...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Inflammatory bowel diseases Ročník 19; číslo 4; s. 754 - 760
Hlavní autori: Mayer, Lloyd, Pandak, William M., Melmed, Gil Y., Hanauer, Stephen B., Johnson, Kristine, Payne, Denise, Faleck, Herbert, Hariri, Robert J., Fischkoff, Steven A.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Oxford University Press 01.03.2013
Predmet:
Adolescent
Adult
Aged
Aged, 80 and over
Cell- and Tissue-Based Therapy
Cells, Cultured
Crohn Disease - therapy
Crohn's disease
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Placenta - cytology
Pregnancy
Remission (Medicine)
Remission Induction
Salvage Therapy
Surveys and Questionnaires
Treatment Outcome
Treatment resistance
Young Adult
ISSN:1078-0998, 1536-4844, 1536-4844
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The clinical utility of cellular therapies is being investigated in a broad range of therapeutic areas. This phase 1 study represents the first exploration of PDA001, a preparation of cells cultured from human placental tissue, in subjects with Crohn's disease. Twelve subjects with active, moderate-to-severe Crohn's disease unresponsive to previous therapy were given 2 intravenous infusions of PDA001 1 week apart, monitored weekly for 5 weeks, and assessed at 6 months, 1 year, and 2 years after infusion. Six subjects received 2 infusions of 2 × 10 cells (low dose), and 6 subjects received 2 infusions of 8 × 10 cells (high dose). Mean baseline Crohn's Disease Activity Index in the low-dose and high-dose groups was 305 and 364, respectively, and mean C-reactive protein was 8 mg/L and 49 mg/L, respectively. All subjects in the low-dose group achieved a clinical response (a Crohn's Disease Activity Index decrease of ≥70 points versus baseline), and 3 achieved remission (a Crohn's Disease Activity Index decrease of ≥100 to <150 points). Two subjects in the high-dose group achieved response, and none met remission criteria. Most adverse events were mild to moderate in severity and included headache, nausea, fever, and infusion site reactions. PDA001 infusions appear safe and well-tolerated in subjects with treatment-resistant Crohn's disease. A response was seen in all subjects in the low-dose group. The high-dose group, with a higher baseline disease activity, had only 2 responders, suggesting a more treatment-resistant population. A phase 2 study in this patient population is ongoing.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1078-0998
1536-4844
1536-4844
DOI:10.1097/MIB.0b013e31827f27df